0001415889-24-002161.txt : 20240201
0001415889-24-002161.hdr.sgml : 20240201
20240201160009
ACCESSION NUMBER: 0001415889-24-002161
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240131
FILED AS OF DATE: 20240201
DATE AS OF CHANGE: 20240201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LILLY ENDOWMENT INC
CENTRAL INDEX KEY: 0000316011
ORGANIZATION NAME:
STATE OF INCORPORATION: IN
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-06351
FILM NUMBER: 24586811
BUSINESS ADDRESS:
STREET 1: 2801 NORTH MERIDIAN STREET
CITY: INDIANANAPOLIS
STATE: IN
ZIP: 46208
BUSINESS PHONE: 3179245471
MAIL ADDRESS:
STREET 1: 2801 NORTH MERIDIAN ST
CITY: INDIANAPOLIS
STATE: IN
ZIP: 46208
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ELI LILLY & Co
CENTRAL INDEX KEY: 0000059478
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 350470950
STATE OF INCORPORATION: IN
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: LILLY CORPORATE CTR
STREET 2: DROP CODE 1094
CITY: INDIANAPOLIS
STATE: IN
ZIP: 46285
BUSINESS PHONE: 3172762000
MAIL ADDRESS:
STREET 1: LILLY CORPORATE CENTER
STREET 2: DROP CODE 1094
CITY: INDIANAPOLIS
STATE: IN
ZIP: 46285
FORMER COMPANY:
FORMER CONFORMED NAME: LILLY ELI & CO
DATE OF NAME CHANGE: 19941024
4
1
form4-02012024_040201.xml
X0508
4
2024-01-31
0000059478
ELI LILLY & Co
LLY
0000316011
LILLY ENDOWMENT INC
2801 NORTH MERIDIAN STREET
INDIANAPOLIS
IN
46208-0068
false
false
true
false
0
Common Stock
2024-01-31
4
S
0
35506
645.282
D
99376877
D
Common Stock
2024-01-31
4
S
0
9169
646.41
D
99367708
D
Common Stock
2024-01-31
4
S
0
8696
647.532
D
99359012
D
Common Stock
2024-01-31
4
S
0
7424
648.598
D
99351588
D
Common Stock
2024-01-31
4
S
0
4931
649.803
D
99346657
D
Common Stock
2024-01-31
4
S
0
815
650.729
D
99345842
D
Common Stock
2024-01-31
4
S
0
900
651.56
D
99344942
D
Common Stock
2024-01-31
4
S
0
1900
654.252
D
99343042
D
Common Stock
2024-01-31
4
S
0
2750
655.265
D
99340292
D
Common Stock
2024-01-31
4
S
0
1700
656.302
D
99338592
D
Common Stock
2024-01-31
4
S
0
600
657.398
D
99337992
D
Common Stock
2024-01-31
4
S
0
1700
658.651
D
99336292
D
Common Stock
2024-01-31
4
S
0
797
659.64
D
99335495
D
Common Stock
2024-01-31
4
S
0
985
661.088
D
99334510
D
Common Stock
2024-01-31
4
S
0
200
661.63
D
99334310
D
Common Stock
2024-01-31
4
S
0
500
662.808
D
99333810
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $645.00 to $645.95, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), and (15) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $646.00 to $646.99, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $647.07 to $648.0202, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $648.115 to $649.11, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $649.185 to $650.00, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $650.235 to $651.00, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $651.3174 to $651.83, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $653.765 to $654.76, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $654.765 to $655.60, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $655.86 to $656.635, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $656.98 to $657.87, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $658.11 to $658.94, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $659.185 to $660.0675, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $660.5246 to $661.23, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $662.65 to $663.025, inclusive.
/s/ Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc.
2024-02-01